SR-717
Catalog No.: GC61293Purity:>99.50%
SR-717 is a non-nucleotide STING agonist. SR-717 activates STING in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cells (EC50=2.1μM, 2.2μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2375421-09-1
10mM (in 1mL DMSO)In Stock
$116.00
1
1mgIn Stock
$48.00
1
5mgIn Stock
$105.00
1
10mgIn Stock
$175.00
1
25mgIn Stock
$315.00
1
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $116.00 | In Stock | 1 | |
| 1mg | $48.00 | In Stock | 1 | |
| 5mg | $105.00 | In Stock | 1 | |
| 10mg | $175.00 | In Stock | 1 | |
| 25mg | $315.00 | In Stock | 1 |
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com
Citations
1 publicationsPublications from researchers using this productDescription
SR-717 is a non-nucleotide STING agonist. SR-717 activates STING in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cells (EC50=2.1μM, 2.2μM). SR-717 acts as a cGAMP mimetic to induce the closed conformation of STING protein. SR-717 thereby activates downstream phosphorylation of TBK1, IRF3 and STAT3 and promotes IFN-β expression. SR-717 promotes infiltration and activation of immune cells such as CD8+ T cells and NK cells, thereby inhibiting tumor growth. SR-717 can be used for cancer and inflammation/immunity related research[1-4].
In vitro, SR-717 (10μM) treatment of Caski and HeLa cervical cancer cells for 6h reduced HPV16/18 E7 oncoprotein levels and inhibited cell proliferation and colony formation[5]. SR-717 (10μM) treatment of DC2.4 cells for 24h upregulated p-TBK1 and p-IRF3 expression, promoted IFN-β secretion, and upregulated CD80 and CD86 expression to promote dendritic cell maturation[6]. SR-717 (20μM) treatment of MODE-K cells for 12h increased cell viability, inhibited apoptosis, and upregulated expression of STING, p-TBK1, p-p65, STAT3, and p-STAT3[7].
In vivo, intratumoral injection of SR-717 (30mg/kg) into A/J mice and C57BL/6 mice bearing Neuro-2A neuroblastoma cells and CT-2A glioblastoma cells every 3 days for 3 cycles significantly inhibited tumor growth of neuroblastoma and glioblastoma[8]. In neonatal mice at postnatal day 5, after induction of germinal matrix hemorrhage, a single intraperitoneal injection of SR-717 (30mg/kg) was administered immediately. SR-717 increased the number of microglia and proinflammatory cytokine levels in the perilesional area and aggravated the decrease of tight junction proteins ZO-1 and occludin[9]. In C57BL/6J mice with femoral fracture, daily intraperitoneal injection of SR-717 (30mg/kg) for 1 week promoted fracture healing, manifested as increased bone structural parameters such as bone tissue volume, bone volume fraction, and bone mineral density, and increased cartilage formation[10].
References:
[1] Chin EN, Yu C, Vartabedian VF, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020 Aug 21;369(6506):993-999.
[2] Wang J, Geng T, Yao X, et al. GDF15 attenuates Parkinson's disease progression via suppressing the activation of cGAS-STING pathway. Molecular and Cellular Biochemistry. 2025;480:4449-4466.
[3] Fu H, Guo X, Fang F, et al. STING pathway activation with cisplatin polyprodrug nanoparticles for chemo-immunotherapy in ovarian cancer. J Control Release. 2025 May 10;381:113565.
[4] Caldwell SE, Janosko CP, Deiters A. Development of a light-activated STING agonist. Org Biomol Chem. 2024 Jan 3;22(2):302-308.
[5] Huang X, Huo L, Xiao B, et al. Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. Cell Death Differ. 2024;31(1):78-89.
[6] Miao Z, Song X, Xu A, et al. Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers. Pharmaceutics. 2024 Sep;16(9):1216.
[7] Fang D, Duan W, Zhai X, et al. SR-717, a Non-Nucleotide STING Agonist, Displayed Anti-Radiation Activity in a IL-6 Dependent Manner. The FASEB Journal. 2025;39:e70644.
[8] Lv Z, Wang T, Fan R, et al. Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression. Cancer Biol Med. 2026;23:133-153.
[9] Wang Y, Yin X, Zhang X, et al. Inhibition of cGAS reduces brain injury and facilitates neurological recovery via the STING-mediated signaling pathway after germinal matrix hemorrhage in neonatal mice. J Integr Neurosci. 2025;24(8):39286.
[10] Zheng M, Zhao L, Nian S, et al. cGAS-STING pathway mediation in osteoclast function and bone fracture healing. Front Immunol. 2026;17:1789655.
Protocol
| Cell experiment [1]: | |
|
Cell lines |
DC2.4 cells (mouse dendritic cell line), RAW264.7 cells (mouse macrophage cell line) |
|
Preparation Method |
DC2.4 cells were maintained in RPMI 1640 medium supplemented with 10% FBS at 37°C, 5% CO2. Cells were treated with SR-717 at 10μM for 24 hours, followed by western blot analysis of p-TBK1 and p-IRF3, ELISA for IFN-β, and flow cytometry for CD80 and CD86 expression. RAW264.7 cells were polarized to M2 phenotype and then treated with SR-717 at 10μM for 24 hours, followed by flow cytometry for CD206 and CD86 expression. |
|
Reaction Conditions |
10μM; 24h |
|
Applications |
SR-717 increased phosphorylation of TBK1 and IRF3. SR-717 elevated IFN-β production. SR-717 decreased CD206 expression and increased CD86 expression on macrophages. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6J mice |
|
Preparation Method |
6-8-week-old male C57BL/6J mice were subjected to femoral fracture surgery. From the day after surgery, mice were intraperitoneally administered SR-717 at 30mg/kg daily for one week, followed by micro-CT scanning at 2 and 4 weeks post-surgery, and safranin O-fast green staining and TRAP staining of femoral specimens at 14 days post-fracture for tissue analysis. |
|
Dosage form |
30mg/kg; i.p.; daily for one week |
|
Applications |
SR-717 increased bone tissue volume, bone volume fraction and bone mineral density. SR-717 increased STING protein expression in callus tissue. SR-717 increased cartilage area. SR-717 increased TRAP-positive osteoclast number on bone surface. |
References: [1] Miao Z, Song X, Xu A, et al. Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers. Pharmaceutics. 2024 Sep;16(9):1216. [2] Zheng M, Zhao L, Nian S, et al. cGAS-STING pathway mediation in osteoclast function and bone fracture healing. Front Immunol. 2026;17:1789655. | |
Product Documents
Purity:>99.50%Appearance:A solid
Chemical Properties
CAS No.
2375421-09-1
SMILES
O=C(O[Li])C1=CC(F)=C(F)C=C1NC(C2=NN=C(N3C=CN=C3)C=C2)=O
Molecular Formula
C15H8F2LiN5O3
Molecular Weight
351.19
Solubility
DMSO: 14.29 mg/mL (40.69 mM); Water: < 0.1 mg/mL (insoluble)
Storage
Store at -20°C
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
g/mol
Reviews
Review for SR-717
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%